PaulAFrohnaMDPhD, PharmD

Chief Medical & Scientific Officer, ImCheck Therapeutics (Marseille, FRANCE) Developing drugs for immuno-oncology, infectious diseases and autoimmune disorders.

Join to view full profile

Dr. Frohna is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Frohna's full profile

Already have an account?

Office
Marseille, France
Solana Beach, CA 92075

Summary

Paul Frohna, MD, PhD, is a researcher in Marseille, France. He received his medical degree from Georgetown University School of Medicine and has been doing clinical research for 20 years. He does not see patients. He is experienced in translational medicine and clinical trials in immuno-oncology, immunology, multiple sclerosis, Alzheimer's disease and regenerative medicine.

Education & Training

University of Texas at Austin Dell Medical SchoolInternship, Internal Medicine, 2000 - 2001
Georgetown University School of MedicineClass of 2000

Clinical Trials

U.S. Study of Fibrocaps in Surgical Hemostasis Start of enrollment: 2010 Dec 01
Completed
Not Applicable
A Study of Fibrocaps in Liver Surgery in the Netherlands Start of enrollment: 2010 Dec 01
Completed
Phase 2
A Study of Fibrocaps™ in Surgical Bleeding Start of enrollment: 2012 May 21
Completed
Phase 3
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis Start of enrollment: 2013 Dec 03
Completed
Phase 3
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Start of enrollment: 2014 Aug 31
Completed
Phase 2
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis Start of enrollment: 2015 Jun 17
Completed
Phase 3
A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects Start of enrollment: 2017 Oct 30
Completed
Phase 1
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL Start of enrollment: 2018 Apr 01
Completed
Phase 1, Phase 2
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata Start of enrollment: 2021 Oct 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

32 citations
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study:
Jeffrey A. Cohen, Giancarlo Comi, Douglas L. Arnold, Amit Bar-Or, Krzysztof Selmaj
Multiple Sclerosis. 2019-08-01
156 citations
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Ikuo Hirano, Margaret H. Collins, Yehudith Assouline-Dayan, Larry Evans, Sandeep K. Gupta
Gastroenterology. 2019-02-01
21 citations
Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
Jonathan Q. Tran, Jeffrey P. Hartung, Cindy-ann Tompkins, Paul A. Frohna
Clinical Pharmacology in Drug Development. 2018-08-01

Press Mentions

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual MeetingNovember 11th, 2022
Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022September 10th, 2022
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021September 17th, 2021
Join now to see all